Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
Public ClinicalTrials.gov record NCT01087762. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
Study identification
- NCT ID
- NCT01087762
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- UCB BIOSCIENCES GmbH
- Industry
- Enrollment
- 325 participants
Conditions and interventions
Conditions
Interventions
- CZP 200 mg Q2W Biological
- CZP 400 mg Q4W Biological
- Placebo Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2010
- Primary completion
- Sep 30, 2011
- Completion
- Jul 31, 2015
- Last update posted
- Jul 31, 2018
2010 – 2015
United States locations
- U.S. sites
- 32
- U.S. states
- 17
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 961 | Birmingham | Alabama | — | — |
| 953 | Tuscaloosa | Alabama | — | — |
| 954 | Peoria | Arizona | — | — |
| 971 | Scottsdale | Arizona | — | — |
| 987 | Tucson | Arizona | — | — |
| 974 | La Jolla | California | — | — |
| 973 | Los Angeles | California | — | — |
| 966 | Palm Desert | California | — | — |
| 952 | San Diego | California | — | — |
| 957 | Aventura | Florida | — | — |
| 962 | Fort Lauderdale | Florida | — | — |
| 959 | Orange Park | Florida | — | — |
| 990 | Pinellas Park | Florida | — | — |
| 958 | Vero Beach | Florida | — | — |
| 964 | Hagerstown | Maryland | — | — |
| 969 | Eagan | Minnesota | — | — |
| 984 | Flowood | Mississippi | — | — |
| 965 | Florissant | Missouri | — | — |
| 950 | St Louis | Missouri | — | — |
| 985 | Brooklyn | New York | — | — |
| 963 | Asheville | North Carolina | — | — |
| 977 | Cleveland | Ohio | — | — |
| 951 | Middleburg Heights | Ohio | — | — |
| 970 | Oklahoma City | Oklahoma | — | — |
| 982 | Portland | Oregon | — | — |
| 972 | Duncansville | Pennsylvania | — | — |
| 975 | Dallas | Texas | — | — |
| 978 | Houston | Texas | — | — |
| 983 | Houston | Texas | — | — |
| 967 | San Antonio | Texas | — | — |
| 981 | Salt Lake City | Utah | — | — |
| 968 | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 72 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01087762, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 31, 2018 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01087762 live on ClinicalTrials.gov.